Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.

CONFIDHENCE

Comprehensive Cancer Center Mainfranken

Leukämien

Akute myeloische Leukämie (AML)

Anwendungsbeobachtung

Herr Dr. Manfred Welslau

Frau Dr. Simone Liebler

Hämato-Onkologische Schwerpunktpraxis (MVZ) am Klinikum Aschaffenburg Dr. Welslau

Herr Dr. med. Harald Biersack

Medizinische Klinik II, Gastroenterologie, Onkologie und Palliativmedizin

Klinikum Kulmbach

Beobachtend, Resultatsorientiert, Epidemiologisch